Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Subaxone

- PMLiVE

As the opioid crisis grabs the headlines, the search for safe treatments continues

Indivior’s Gilles Picard charts a path to greater patient access and new therapies

- PMLiVE

Reckitt hammered by $1.4bn opioid settlement bill

Case centres on Subaxone marketing practices

- PMLiVE

UK to add addiction warnings to opioids as use soars

Codeine-related deaths doubled in a decade

- PMLiVE

Indivior push to diversify boosted by schizophrenia drug approval

Perseris will face competition from Lundbeck/Otsuka’s Abilify Maintena and J&J’s Invega Sustenna

- PMLiVE

GSK joins Reckitt in passing on Pfizer’s consumer health unit

The healthcare business doesn’t meet GSK’s criteria for returns, says Walmsley

- PMLiVE

FDA panel backs Indivior’s drug to fight opioid addiction

The former RB pharma unit hopes for sales in the $1bn region

- PMLiVE

Indivior slumps as patent dispute rises US generic spectre

The RB spin out will appeal against the ruling

- PMLiVE

RB and Lions Health hold air pollution innovation hack

The second annual event will focus on China

- PMLiVE

FDA gives green light for opioid addiction implant

Titan and Braeburn's Probuphine is first implant of its kind to win US approval

- PMLiVE

FDA panel backs approval of first opioid addiction implant

Probuphine has been developed by Titan Pharma and partner Braeburn Pharma

- PMLiVE

Reckitt to spin-off pharma unit as Indivior

Demerged business will focus on opioid dependence product Suboxone

- PMLiVE

Reckitt Benckiser confirms pharma spin-off plans

Will separate prescription and consumer health businesses

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links